As two approved malaria vaccines ramp up production to meet demand in 2025, an innovative booster vaccine candidate has been found to enhance immunity and reduce the number of cases and related fatalities.
According to the results of a phase 2b clinical trial, the RH5.1/Matrix-MTM malaria vaccine was 55% effective in preventing clinical malaria over six months.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
